Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture.
METHODS: Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB.
PRIMARY OUTCOME: early-PJI after HHA.
RESULTS: Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]).
CONCLUSIONS: Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 40(2021), 11 vom: 16. Nov., Seite 2411-2419 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodríguez-Pardo, Dolors [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 23.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-021-04241-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32418834X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32418834X | ||
| 003 | DE-627 | ||
| 005 | 20231225185801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-021-04241-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM32418834X | ||
| 035 | |a (NLM)33864153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodríguez-Pardo, Dolors |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 23.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture | ||
| 520 | |a METHODS: Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB | ||
| 520 | |a PRIMARY OUTCOME: early-PJI after HHA | ||
| 520 | |a RESULTS: Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]) | ||
| 520 | |a CONCLUSIONS: Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Asymptomatic bacteriuria | |
| 650 | 4 | |a Early-periprosthetic joint infection | |
| 650 | 4 | |a Fosfomycin-trometamol | |
| 650 | 4 | |a Hip hemiarthroplasty | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Tromethamine |2 NLM | |
| 650 | 7 | |a 023C2WHX2V |2 NLM | |
| 650 | 7 | |a Fosfomycin |2 NLM | |
| 650 | 7 | |a 2N81MY12TE |2 NLM | |
| 700 | 1 | |a Del Toro, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Guío-Carrión, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero-Sánchez, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Sampedro, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a García-Viejo, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Velasco-Arribas, María |e verfasserin |4 aut | |
| 700 | 1 | |a Soldevila-Boixader, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Femenias, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Iribarren, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pulido-Garcia, María Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Lung, Mayli |e verfasserin |4 aut | |
| 700 | 1 | |a Corona, Pablo S |e verfasserin |4 aut | |
| 700 | 1 | |a Almirante, Benito |e verfasserin |4 aut | |
| 700 | 1 | |a Pigrau, Carles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 40(2021), 11 vom: 16. Nov., Seite 2411-2419 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2021 |g number:11 |g day:16 |g month:11 |g pages:2411-2419 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-021-04241-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2021 |e 11 |b 16 |c 11 |h 2411-2419 | ||